Doctors now limit Fosamax prescriptions to roughly five years because the drug’s risks begin to outweigh its benefits beyond that point. In 2012, the FDA issued a safety communication concluding that the advantages of long-term bisphosphonate use beyond three to five years are unclear for many patients, and recommended that healthcare providers periodically reassess the need for continued therapy. The shift was driven largely by mounting evidence linking prolonged use to rare but devastating complications, including atypical femur fractures and osteonecrosis of the jaw — problems that become significantly more likely the longer a patient stays on the medication. This wasn’t always the thinking.
For years after Fosamax (generic name: alendronate) hit the market in 1995, many doctors prescribed it indefinitely, assuming that if a little bone protection was good, more was better. A woman diagnosed with osteoporosis at 60 might still be taking it at 75. The landmark FLEX trial, published in JAMA in 2006, changed that calculus by showing that women who stopped alendronate after five years maintained bone density at most skeletal sites with no significant increase in overall fracture risk. That finding, combined with growing alarm about atypical fractures, ushered in the era of the “drug holiday” — a concept that would have seemed reckless a decade earlier. This article covers why the five-year window became the standard, what happens to your bones when you stop, the specific complications that forced the change, how drug holidays actually work, and what this means if you or a family member is currently taking Fosamax.
Table of Contents
- Why Do Doctors Now Only Prescribe Fosamax for 5 Years Maximum?
- Atypical Femur Fractures — The Risk That Changed Everything
- Osteonecrosis of the Jaw and Other Long-Term Complications
- How Drug Holidays Work and When They Don’t
- The Litigation That Brought Fosamax Into Public View
- What This Means for Dementia Caregivers
- Where Osteoporosis Treatment Is Heading
- Conclusion
- Frequently Asked Questions
Why Do Doctors Now Only Prescribe Fosamax for 5 Years Maximum?
The short answer is that bisphosphonates like Fosamax have an extraordinarily long half-life in bone tissue — roughly ten years. The drug binds tightly to the mineral surface of bone and continues suppressing the cells that break down old bone (osteoclasts) long after a patient swallows the last tablet. This means the medication keeps working even after you stop taking it, which makes prolonged continuous use both unnecessary and potentially harmful for many patients. The American Society for Bone and Mineral Research (ASBMR) task force formalized this in updated recommendations, advising that after five years of oral bisphosphonates, patients at moderate fracture risk should take a drug holiday of two to three years, with periodic reassessment. High-risk patients — those with prior vertebral fractures or very low bone density — may continue longer, but even they should be reevaluated regularly.
The American Association of Clinical Endocrinologists (AACE) issued similar guidance in 2020, recommending reassessment after five years of oral therapy. Consider the difference between a 68-year-old woman with mild osteopenia and no fracture history versus a 74-year-old woman who has already broken two vertebrae. The first patient is a textbook candidate for a drug holiday after five years. The second may need to continue, but her doctor should still be weighing the accumulating risks against the fracture protection. The era of open-ended prescriptions is over.
Atypical Femur Fractures — The Risk That Changed Everything
The complication that did the most to reshape prescribing habits was the atypical femoral fracture. Unlike the hip fractures that Fosamax was designed to prevent — which typically occur at the femoral neck — atypical fractures strike the shaft of the thighbone, often with little or no trauma. A patient might be walking across a parking lot and feel a snap. These fractures are difficult to heal and frequently require surgical rodding. A 2011 study published in JAMA quantified the risk in stark terms. The incidence of atypical femoral fractures was approximately 2 per 100,000 patient-years with short-term bisphosphonate use.
After eight or more years of continuous therapy, that figure jumped to roughly 78 per 100,000 patient-years — a nearly 40-fold increase. The FDA subsequently updated Fosamax’s labeling to include warnings about atypical fractures, and these findings were central to the agency’s 2012 safety review. However, it is critical to understand that these fractures remain rare in absolute terms, even with long-term use. The overwhelming majority of patients who took Fosamax for a decade never experienced one. The problem is that bisphosphonates work by suppressing bone remodeling — the natural process by which old, damaged bone is replaced. Over many years, this can lead to brittle, overly mineralized bone that is paradoxically more vulnerable to certain types of fractures. If you are currently taking Fosamax and experience dull, aching thigh pain, report it to your doctor immediately, as this can be an early warning sign of an impending atypical fracture.
Osteonecrosis of the Jaw and Other Long-Term Complications
Atypical femur fractures were not the only red flag. Osteonecrosis of the jaw (ONJ) — a condition where bone tissue in the jaw dies and becomes exposed through the gums — emerged as another rare but serious side effect of prolonged bisphosphonate therapy. The American Dental Association and the American Medical Association have both acknowledged the link, particularly in patients on long-term treatment. ONJ is more common in cancer patients receiving high-dose intravenous bisphosphonates, but cases have been documented in osteoporosis patients taking oral Fosamax as well. The risk is especially relevant for patients who need dental surgery. Tooth extractions, implant placement, and other invasive dental procedures can trigger ONJ in patients with years of bisphosphonate exposure.
Many oral surgeons now ask patients how long they have been on these medications before performing procedures. A patient who has taken Fosamax for three years faces a different risk profile than one who has been on it for nine. Some dentists will request a drug holiday before major jaw surgery, though the evidence on whether this meaningfully reduces risk is still debated. For caregivers managing an older adult’s health — particularly someone with cognitive decline — tracking medication duration is essential. A person with dementia may not be able to articulate thigh pain or jaw symptoms, and the prescribing history may be scattered across multiple providers. If you are coordinating care for a parent or spouse, make sure every doctor and dentist involved knows the full bisphosphonate timeline.
How Drug Holidays Work and When They Don’t
A drug holiday is not the same as quitting a medication. It is a planned, monitored pause. After five years of oral Fosamax, a doctor assesses the patient’s current fracture risk — typically through a DEXA bone density scan and a review of fracture history — and decides whether it is safe to stop. If the patient is at moderate risk, the standard recommendation is a holiday of two to three years, followed by reassessment. The FLEX trial provided the scientific backbone for this approach. Women who switched from alendronate to placebo after five years maintained bone density at the hip and most other sites.
There was a modest increase in vertebral fracture risk in the placebo group, but overall nonvertebral fracture rates were similar. The takeaway was that for most patients, Fosamax’s residual effects in bone tissue provide ongoing protection even after discontinuation. This is a meaningful tradeoff: you lose a small amount of vertebral protection but substantially reduce your exposure to atypical fractures and ONJ. The holiday concept does not work for every patient. Those with very low T-scores (below -2.5 at the hip), a history of vertebral compression fractures, or ongoing glucocorticoid use may not be able to safely pause therapy. For these individuals, options include switching to a different class of medication — such as denosumab (Prolia) or the anabolic agent teriparatide (Forteo) — rather than simply continuing Fosamax indefinitely. Stopping denosumab, notably, carries its own risks, including rapid bone loss and rebound vertebral fractures, so transitions between osteoporosis drugs require careful planning.
The Litigation That Brought Fosamax Into Public View
The medical concerns about Fosamax did not stay confined to academic journals. Merck, the drug’s manufacturer, faced thousands of lawsuits from patients who alleged that Fosamax caused their femur fractures. The litigation peaked in the early 2010s, with cases consolidated in a New Jersey federal court. In a 2013 bellwether trial, a jury awarded $27.5 million to a plaintiff — a verdict that was later reduced — and Merck eventually settled approximately 1,200 cases. The lawsuits raised important questions about what Merck knew and when. Plaintiffs argued that the company had evidence of atypical fracture risks but was slow to update its warnings.
Merck maintained that Fosamax’s benefits outweighed its risks and that it had acted appropriately. Regardless of the legal outcomes, the litigation had a chilling effect on long-term prescribing. Doctors who had been comfortable writing indefinite Fosamax prescriptions became far more cautious, and patients who saw news coverage of the lawsuits began questioning their own prescriptions. One limitation of the litigation narrative is that it can create outsized fear. Some patients stopped Fosamax abruptly without consulting their doctors, which is not advisable. The drug is genuinely effective at preventing fractures during those first five years, particularly vertebral and hip fractures in high-risk patients. Walking away from a medication that is still in its effective window because of a lawsuit headline is not the same as making an informed medical decision to take a drug holiday after appropriate treatment duration.
What This Means for Dementia Caregivers
Osteoporosis management in people with dementia presents unique challenges. A fall that might bruise a healthy 70-year-old can break the hip of someone with untreated osteoporosis, and hip fractures in dementia patients carry significantly higher mortality rates. At the same time, a person with moderate-to-advanced dementia may struggle with Fosamax’s notoriously strict dosing requirements — the pill must be taken on an empty stomach, first thing in the morning, with a full glass of water, and the patient must remain upright for at least 30 minutes afterward.
If your family member has been on Fosamax for approaching five years, initiate a conversation with their prescribing physician about the plan. Do not wait for the doctor to bring it up. Ask specifically about fracture risk reassessment, whether a DEXA scan is warranted, and whether a drug holiday or medication switch makes sense given the patient’s overall health trajectory and fall risk.
Where Osteoporosis Treatment Is Heading
The five-year limit on Fosamax reflects a broader shift in how medicine thinks about chronic disease management — away from indefinite therapy and toward treatment courses with defined endpoints and reassessment intervals. Newer osteoporosis drugs are being developed with this philosophy in mind. Romosozumab (Evenity), approved in 2019, is prescribed as a 12-month course that builds bone before a patient transitions to a maintenance therapy.
The field is moving toward sequential treatment strategies rather than single-drug-forever approaches. For patients and caregivers navigating these decisions now, the most important takeaway is that osteoporosis treatment should never run on autopilot. The five-year mark is not arbitrary — it is grounded in clinical trial data, FDA review, and professional society guidelines. Whether the next step is a drug holiday, a switch to a different medication, or continued therapy with closer monitoring depends on individual risk factors that only a thorough medical assessment can determine.
Conclusion
Fosamax remains an effective medication for reducing fracture risk during its recommended treatment window. The shift to a five-year limit was driven by clear evidence — from the FLEX trial, the 2011 JAMA atypical fracture data, and the FDA’s 2012 safety review — that prolonged use accumulates rare but serious risks without proportional additional benefit for most patients. Drug holidays work because bisphosphonates persist in bone tissue for years after discontinuation, providing a residual protective effect.
If you or someone you care for is currently taking Fosamax, the actionable step is straightforward: know how long the medication has been prescribed, and make sure a reassessment conversation happens around the five-year mark. Ask about DEXA results, fracture history, and whether a pause or medication change is appropriate. Do not stop the medication on your own, and do not let it continue indefinitely without a deliberate decision from a physician who has reviewed the current evidence.
Frequently Asked Questions
Can I just stop taking Fosamax on my own after five years?
No. While the five-year reassessment is well-supported by evidence, discontinuation should be a medical decision. Your doctor needs to evaluate your current bone density, fracture risk, and whether you need to transition to a different medication rather than simply stopping.
Will my bones weaken quickly after I stop Fosamax?
For most patients, no. The FLEX trial showed that bone density at the hip and most other sites remained stable after discontinuation. Bisphosphonates have an extremely long half-life in bone — roughly ten years — so their effects taper gradually. Some decline in vertebral protection may occur, which is why monitoring continues during a drug holiday.
What are the warning signs of an atypical femur fracture?
Dull, aching pain in the thigh or groin that develops gradually is the most common early symptom. This pain may be present for weeks or months before a fracture occurs. If you experience new or unexplained thigh pain while on a bisphosphonate, contact your doctor promptly for imaging.
Is Fosamax safe if I need dental work?
For patients who have been on Fosamax for a short period (under three years) with no other risk factors, the risk of osteonecrosis of the jaw from dental procedures is very low. For long-term users, discuss your bisphosphonate history with both your dentist and prescribing doctor before any invasive dental surgery such as extractions or implant placement.
Are there alternatives to Fosamax for osteoporosis?
Yes. Other bisphosphonates (risedronate, ibandronate, zoledronic acid) work similarly but have different dosing schedules. Non-bisphosphonate options include denosumab (Prolia), which works differently but carries rebound fracture risk if stopped abruptly, and anabolic agents like teriparatide (Forteo) and romosozumab (Evenity), which actively build new bone rather than just slowing bone loss.
Does the five-year rule apply to all bisphosphonates or just Fosamax?
The five-year reassessment guideline applies to all oral bisphosphonates, including risedronate (Actonel) and ibandronate (Boniva). For intravenous zoledronic acid (Reclast), which is given once yearly, the ASBMR recommends reassessment after three years of treatment due to its higher potency.
